ROCÍO
GARCÍA CARBONERO
Profesora titular de universidad
Hospital Ramón y Cajal
Madrid, EspañaHospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (40)
2024
-
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74
-
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)
Nature Communications, Vol. 15, Núm. 1
-
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413
2023
-
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
Genome Medicine, Vol. 15, Núm. 1
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
-
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388
-
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2692-2706
2022
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
2021
-
Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors
Cancers, Vol. 13, Núm. 15
-
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)
ESMO Open, Vol. 6, Núm. 2
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
-
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000
-
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial
Oncologist, Vol. 26, Núm. 11, pp. 941-949
2020
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
-
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
Therapeutic Advances in Endocrinology and Metabolism, Vol. 10
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544